Unknown

Dataset Information

Achieving Optimal Medical Therapy: Insights From the ORBITA Trial.


ABSTRACT: Background In stable coronary artery disease, medications are used for 2 purposes: cardiovascular risk reduction and symptom improvement. In clinical trials and clinical practice, medication use is often not optimal. The ORBITA (Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina) trial was the first placebo-controlled trial of percutaneous coronary intervention. A key component of the ORBITA trial design was the inclusion of a medical optimization phase, aimed at ensuring that all patients were treated with guideline-directed truly optimal medical therapy. In this study, we report the medical therapy that was achieved. Methods and Results After enrollment into the ORBITA trial, all 200 patients entered a 6-week period of intensive medica

SUBMITTER: Foley M 

PROVIDER: S-EPMC7955412 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature